All In Biotech

Drug Trial Radar · NCT03526835

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

May 2, 2018

Primary completion

May 2028

Study completion Nov 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
May 16, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.

Conditions

  • Advanced/Metastatic Solid Tumors
  • Colorectal Cancer
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • NSCLC
  • HNSCC
  • Head and Neck Squamous Cell Carcinoma
  • Esophageal Cancer

Interventions

  • MCLA-158Drug

    full-length IgG1 bispecific antibody targeting EGFR and LGR5

  • MCLA-158 + PembrolizumabCombination product

    MCLA-158 in combination with pembrolizumab will be explored first in HNSCC patients eligible to receive pembrolizumab as first-line monotherapy.

  • MCLA-158 + FOLFIRICombination product

    MCLA-158 in combination with FOLFIRI will be explored in mCRC patients with up to 1 line of prior regimen.

  • MCLA-158 + FOLFOXCombination product

    MCLA-158 in combination with FOLFOX will be explored in mCRC patients with up to 1 line of prior regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1Time frame: 4 weeks
  2. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer, and combination cohorts): Safety and tolerability: AEs and SAEsTime frame: 6-12 months
  3. Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Treatment discontinuations and dose modifications due to AEsTime frame: 6-12 months
  4. Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): Best overall response (BOR)Time frame: 36 months
  5. Expansion (Single agent - non-randomized, and combination cohorts): Objective response rate (ORR)Time frame: 36 months
  6. Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEsTime frame: 8 weeks
  7. Expansion: (subcutaneous cohort): Bioavailability of subcutaneous vs intravenous administrationTime frame: 6 weeks
  8. Expansion: (subcutaneous cohort): Area under the concentration versus time curve from time zero to time t [AUC0-t]Time frame: 6 weeks
  9. Expansion: (subcutaneous cohort): Maximum plasma concentration [Cmax]Time frame: 8 weeks
  10. Expansion: (subcutaneous cohort): Minimum plasma drug concentration [Ctrough]Time frame: 6 weeks

Locations

54 sites in 7 countries. Site status is shown where the registry gives one.

  • UCSD

    La Jolla, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Active not recruiting

  • Sharp Healthcare

    San Diego, California · Recruiting

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado · Recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Completed

  • University of Florida

    Gainesville, Florida · Recruiting

  • Sarah Cannon Research Institute (Lake Nona)

    Orlando, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital - Dana Farber

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Completed

  • SSM Health Saint Louis University Hospital

    St Louis, Missouri · Completed

  • Washington University School of Medicine at St Louis

    St Louis, Missouri · Recruiting

  • Cayuga Medical Center

    Ithaca, New York · Recruiting

  • Mt. Sinai

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Hematology-Oncology Associates of Central New York

    Syracuse, New York · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • SSM OKC Hightower Clinical

    Oklahoma City, Oklahoma · Completed

  • University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • The University Of Tennessee Health Science Center

    Memphis, Tennessee · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Completed

  • Texas Oncology

    Dallas, Texas · Recruiting

  • Oncology Consultants

    Houston, Texas · Recruiting

  • Texas Oncology

    Tyler, Texas · Recruiting

  • Utah Cancer Specialists

    Salt Lake City, Utah · Recruiting

  • University of Utah Health Huntsman Cancer Hospital

    Salt Lake City, Utah · Recruiting

  • Oncology & Hematology Associates of Southwest Virginia

    Roanoke, Virginia · Recruiting

  • Georgetown University Medical Center

    Georgetown, Washington · Recruiting

  • Cancer Care Northwest

    Spokane, Washington · Recruiting

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium · Recruiting

  • Institut Jules Bordet

    Brussels, Belgium · Completed

  • UZ Gent

    Ghent, Belgium · Recruiting

  • Chu Ucl Namur Site De Sainte-Elisabeth

    Namur, Belgium · Recruiting

  • Hopital Saint Andre, CHU Bordeaux

    Bordeaux, France · Recruiting

  • Centre Leon Berard

    Lyon, France · Recruiting

  • Hopital La Timone

    Marseille, France · Active not recruiting

  • Institut Régional du Cancer de Montpellier

    Montpellier, France · Recruiting

  • Centre Antoine Lacassagne

    Nice, France · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.